CHICAGO--(BUSINESS WIRE)--The Illinois Biotechnology Industry Organization—better known as iBIO®-- today announced that through its growing support, Horizon Pharma, has been elevated to an iBIO Leadership Sponsor. Leadership sponsors of iBIO are recognized publicly as being the lead investors in the future of science innovation and commercialization in Illinois
“Horizon is proud to be an iBIO Leadership Sponsor and supports the great work iBIO does to build Illinois and the surrounding Midwest into a leading life sciences community,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma.
iBIO President & CEO Warren Ribley added “We are honored to have Horizon Pharma as a leadership sponsor. Horizon Pharma is a perfect example that successful life sciences companies can be built in Illinois. Their investment and leadership in iBIO will help us ensure the continued growth of our community.”
Horizon Pharma joins a prestigious group including AbbVie, Astellas, Baxter, and Takeda as other iBIO Leadership Sponsors.
iBIO is the champion for the life sciences in Illinois. iBIO’s mission is to make Illinois and the surrounding Midwest one of the world’s top life sciences centers: a great place to do business, and a great place to grow new technology ventures. iBIO, working on its own and through collaboration with our valued partners promotes sound public policy at the local, state, and federal levels; improves our region’s ability to create, attract, and retain businesses; orchestrates industry involvement to help solve America’s math and science education crisis; and builds community by providing opportunities to connect and engage with the industry. We thereby contribute to the well-being of people worldwide through agricultural, bio-industrial and medical applications while creating new jobs, wealth, and prosperity.
About Horizon Pharma
Horizon Pharma is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.